Targeting HER (ERBB) signaling in head and neck cancer: An essential update

被引：30

作者：

Zhang, Jun ^{[1
,2
]}

Saba, Nabil F. ^{[1
]}

Chen, Georgia ^{[1
]}

Shin, Dong M. ^{[1
]}

机构：

[1] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA

[2] Univ Iowa, Carver Coll Med, Holden Comprehens Canc Ctr, Dept Internal Med,Div Hematol Oncol & Blood & Mar, Iowa City, IA 52242 USA

来源：

MOLECULAR ASPECTS OF MEDICINE | 2015年 / 45卷

关键词：

EGFR; HER; ERBB; SCCHN; Targeted therapy; SQUAMOUS-CELL CARCINOMA; EPIDERMAL-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; ACQUIRED-RESISTANCE; EGFR INHIBITORS; NUCLEAR TRANSLOCATION; MUTATIONAL LANDSCAPE; CETUXIMAB RESISTANCE; BISPECIFIC ANTIBODY; CRYSTAL-STRUCTURE;

D O I：

10.1016/j.mam.2015.07.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

HNC (head and neck cancer) remains the 6th most common carcinoma worldwide. The suboptimal survival and toxicities observed with conventional approaches warrant exploration of novel therapeutic strategies such as targeted therapies. Although targeting EGFR (epidermal growth factor receptor) with cetuximab demonstrated clinical promise, HER (human epidermal growth factor receptor) or ERBB (erythroblastic leukemia viral oncogene homolog) targeted therapy in HNC has overall been suboptimal to date in clinical settings. Overcoming the resistance as well as identifying new strategies therefore remains a significant challenge. In this review, we will discuss the emerging roles of HER members besides EGFR. A comprehensive "three-dimensional" view of HER signaling pathway from the importance of EGFR nuclear translocation to our maturing concept of receptors' "spatial regulation", as well as the interdependence and interaction among different HER members will also be addressed to complete an essential update of HER signaling in HNC. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：74 / 86

页数：13

共 113 条

[1] Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 [J].

Agrawal, Nishant ;

Frederick, Mitchell J. ;

Pickering, Curtis R. ;

Bettegowda, Chetan ;

Chang, Kyle ;

Li, Ryan J. ;

Fakhry, Carole ;

Xie, Tong-Xin ;

Zhang, Jiexin ;

Wang, Jing ;

Zhang, Nianxiang ;

El-Naggar, Adel K. ;

Jasser, Samar A. ;

Weinstein, John N. ;

Trevino, Lisa ;

Drummond, Jennifer A. ;

Muzny, Donna M. ;

Wu, Yuanqing ;

Wood, Laura D. ;

Hruban, Ralph H. ;

Westra, William H. ;

Koch, Wayne M. ;

Califano, Joseph A. ;

Gibbs, Richard A. ;

Sidransky, David ;

Vogelstein, Bert ;

Velculescu, Victor E. ;

Papadopoulos, Nickolas ;

Wheeler, David A. ;

Kinzler, Kenneth W. ;

Myers, Jeffrey N. .

SCIENCE, 2011, 333 (6046) :1154-1157

[2] Expression and Mutation Analysis of Her2 in Head and Neck Squamous Cell Carcinoma [J].

Ali, Mahmoud A. L. Sheikh ;

Gunduz, Mehmet ;

Gunduz, Esra ;

Tamamura, Ryo ;

Beder, Levent Bekir ;

Katase, Naoki ;

Hatipoglu, Omer Faruk ;

Fukushima, Kunihiro ;

Yamanaka, Noboru ;

Shimizu, Kenji ;

Nagatsuka, Hitoshi .

CANCER INVESTIGATION, 2010, 28 (05) :495-500

[3]

[Anonymous], CARCINOGENESIS

[4]

[Anonymous], J CLIN ONCOL S

[5]

[Anonymous], CANC RES

[6]

[Anonymous], AFATINIB VS METHOTRE

[7]

[Anonymous], J CLIN ONCOL S

[8]

[Anonymous], CANC RES S

[9]

[Anonymous], ASCO M

[10] Dacomitinib, an Irreversible Pan-ErbB Inhibitor Significantly Abrogates Growth in Head and Neck Cancer Models That Exhibit Low Response to Cetuximab [J].

Ather, Ferdows ;

Hamidi, Habib ;

Fejzo, Marlena S. ;

Letrent, Stephen ;

Finn, Richard S. ;

Kabbinavar, Fairooz ;

Head, Christian ;

Wong, Steven G. .

PLOS ONE, 2013, 8 (02)

← 1 2 3 4 5 6 7 8 9 10 →